TP53 and cancer: The mutant p53 is highly abundant in cancers, and it promotes tumorigenesis by disabling the function of the wild-type p53, as well as by “gain-of-function” processes such as the accumulation of p53 mutations, that augments the oncogenic capacity of the mutated p53 and delivers a stronger tumoral resistance against anti-cancer treatments (156, 157).